AOD-9604 is a synthetic peptide fragment that corresponds to the C-terminal region of human growth hormone (hGH 176–191), modified with a stabilising tyrosine residue at its N-terminus. It belongs to a class of compounds investigated in laboratory settings for their reported effects on lipid metabolism — specifically, the breakdown and oxidation of fat — without engaging the growth-promoting or IGF-1-elevating actions associated with the full growth hormone molecule. Originally assigned the research code "AOD" for anti-obesity drug, this fragment has been the subject of in vitro and animal-model studies exploring how a small portion of a large hormone can retain a discrete metabolic signal. This article examines what AOD-9604 is, its relationship to growth hormone, the mechanisms reported in research, and the laboratory standards relevant to handling and verifying it.
Human growth hormone (hGH) is a 191-amino-acid polypeptide secreted by the anterior pituitary. It is a multifunctional hormone: it drives longitudinal bone growth, stimulates the liver to produce insulin-like growth factor 1 (IGF-1), and exerts a range of metabolic effects, including influence on how the body mobilises and uses stored fat. For decades, researchers asked whether these functions could be separated — whether the metabolic activity directed at adipose tissue lived in a different part of the molecule than the growth-promoting activity.
AOD-9604 emerged from that line of inquiry. It is built around the sequence of the final 16 amino acids of hGH — residues 176 through 191 — which sit at the C-terminal end of the hormone. To improve stability and handling, a single tyrosine residue is added at the N-terminus of this fragment, producing the molecule used in research today. Because it reproduces only a small, defined region of the parent hormone, AOD-9604 is described as a growth hormone fragment rather than a growth hormone analogue in the full sense.
The naming convention is itself a useful clue to the compound's history. The prefix "AOD" stands for anti-obesity drug, a label applied during the early research programmes that characterised the fragment's metabolic profile in laboratory models. The "9604" is a development code. Taken together, the name signals exactly what the molecule was designed to interrogate: whether a fragment of growth hormone could carry a fat-directed signal on its own.
Earlier studies of growth hormone had pointed to its C-terminal portion as the structural neighbourhood associated with lipolytic activity — the hormone's capacity to act on fat cells. AOD-9604 represents an attempt to isolate that neighbourhood. By synthesising the 176–191 sequence as a stand-alone peptide, researchers could test, in controlled conditions, whether the metabolic signal survived separation from the rest of the protein. This is the core scientific rationale behind the fragment and the reason it remains a reference compound in metabolic peptide research.
Full-length growth hormone is a powerful and pleiotropic signalling molecule. In research contexts, that breadth is also a limitation: when you administer the whole hormone to a model system, you engage every pathway it touches at once — growth, IGF-1 production, glucose handling, and lipid metabolism together. Untangling which effect comes from which part of the molecule becomes difficult.
A fragment-based approach offers a way around this. If a short, defined sequence reproduces one specific activity of the parent hormone while leaving the others untouched, it becomes a precise tool for studying that single activity in isolation. This is the conceptual appeal of AOD-9604. The research hypothesis associated with it is that the hGH 176–191 fragment retains the hormone's signal toward fat metabolism while not meaningfully driving the growth and IGF-1 axis that the intact hormone activates.
That proposed separation — often summarised as dissociating the metabolic actions from the growth actions of growth hormone — is the single most important idea to understand about this compound. It is why AOD-9604 is interesting to researchers who want to probe the lipid-handling side of growth hormone biology without simultaneously triggering the systemic growth and IGF-1 responses that complicate interpretation. It is also why the fragment is categorised among weight-loss and metabolic research peptides rather than among growth-hormone secretagogues or growth-promoting compounds.
It is worth stating plainly: the studies that established this profile were conducted in cell cultures and animal models, and any description of AOD-9604's effects here refers to those experimental settings. The fragment is a research reagent, and the observations attached to it belong to the laboratory.
The mechanistic story that researchers have assembled around AOD-9604 centres on adipose tissue — fat cells, or adipocytes — and the two complementary processes that govern how those cells store and release energy: lipolysis and lipogenesis.
Lipolysis is the breakdown of stored triglycerides into free fatty acids that can be released from the fat cell and used as fuel. Lipogenesis is the opposite: the synthesis and storage of new fat. A compound that shifts the balance between these two processes — encouraging breakdown, discouraging storage — would, in principle, reduce the net accumulation of fat in a model system.
In animal models and in vitro adipocyte studies, AOD-9604 has been investigated for its reported capacity to:
Crucially, the literature describes these effects as occurring without the elevation in IGF-1 or the growth-stimulating signalling that full growth hormone produces. This is the experimental embodiment of the dissociation hypothesis: in the models studied, the fat-directed activity appears to be present while the growth-directed activity appears to be largely absent.
The precise molecular details — the receptors, second messengers, and signalling cascades through which the fragment exerts these effects — remain an active and incompletely resolved area of investigation. Some research has explored whether AOD-9604 acts through pathways related to beta-adrenergic signalling in fat cells, which is a well-known regulator of lipolysis, but the full mechanistic picture is not settled. For the purposes of a research summary, the honest framing is this: AOD-9604 is reported in models to favour fat breakdown over fat storage, and the mechanism by which it does so is still being characterised.
Findings from adipocyte cultures and rodent studies describe the behaviour of a compound in those specific systems. They do not translate into claims about humans, and nothing in the research record should be read as establishing an effect outside the laboratory. This distinction is not a legal formality — it is a scientific one. Model systems are simplifications, and the gap between a result in a dish or an animal and an outcome in a living person is large and not bridged by AOD-9604's research literature.
The body of work surrounding AOD-9604 is concentrated in a few thematic areas, all of them tied to lipid metabolism and adipose biology.
Adipocyte studies. Much of the foundational research used isolated fat cells to examine how the fragment influences the lipolysis–lipogenesis balance directly at the cellular level. These in vitro experiments are where the compound's metabolic signature was first defined, and they remain the clearest demonstrations of what the molecule does to fat cells in a controlled environment.
Animal-model metabolic studies. Beyond the cellular level, the fragment has been studied in rodent models to observe its effects on body composition, fat mass, and metabolic parameters in a whole-organism context. This research investigates whether the cellular activity seen in vitro produces measurable changes in an intact animal's fat stores and energy metabolism.
Comparisons with growth hormone. A recurring research theme is the side-by-side comparison of the fragment with full-length growth hormone, designed specifically to test the dissociation hypothesis. These studies ask whether AOD-9604 reproduces the fat-metabolism effects of the parent hormone while diverging from it on the growth and IGF-1 axis.
Cartilage and tissue research. AOD-9604 has also appeared in research outside pure fat metabolism — for example, exploratory work examining the fragment in the context of cartilage and connective tissue. This illustrates that, like many peptides of research interest, the compound's activity has been probed in more than one biological setting, even though its defining characterisation remains metabolic.
Across all of these, the unifying thread is that AOD-9604 functions as a research tool for interrogating the metabolic — and specifically the fat-directed — biology that growth hormone participates in. Researchers working in this space can explore related compounds in the Weight-Loss & Metabolic peptides category.
The table below summarises the defining properties of the fragment as a research compound.
| Property | Detail |
|---|---|
| Classification | Synthetic peptide fragment of human growth hormone (hGH 176–191) |
| Origin / research code | "AOD" = anti-obesity drug; derived from the C-terminal region of hGH with an added N-terminal tyrosine |
| Reported pathway | Lipid metabolism — investigated for effects on lipolysis, lipogenesis, and fat oxidation in models |
| Distinguishing feature | Reported to act on fat metabolism without the growth / IGF-1 signalling of full GH |
| Physical form | Lyophilised (freeze-dried) powder |
| Laboratory storage | Lyophilised powder kept cold (refrigerated; longer-term frozen); reconstituted material refrigerated and used promptly |
| Purity standard | HPLC-verified, supplied with a batch Certificate of Analysis (COA) |
| Status | Research use only — not for human or animal consumption |
AOD-9604 is supplied as a lyophilised powder — a freeze-dried, solid form that maximises stability during shipping and storage. In this dry state, the peptide is comparatively robust, but it is not indefinitely stable at room temperature, and good laboratory practice treats it as a temperature-sensitive reagent from the moment it arrives.
At the laboratory level, reconstitution refers to dissolving the lyophilised powder in an appropriate solvent to produce a working solution for experimental use. Bacteriostatic water or sterile water is commonly used for this purpose in research settings. The solvent is typically introduced slowly against the inside wall of the vial, allowing it to run down onto the powder rather than being forced directly onto it, which helps preserve the integrity of the peptide. The vial is then left to dissolve gently; vigorous shaking is avoided, as mechanical agitation can stress and degrade peptide chains.
Storage practice follows the form of the material:
These practices are standard for handling research peptides and exist to protect the structural integrity — and therefore the experimental reliability — of the compound. They are described here strictly in the context of laboratory bench work with a research reagent.
For any peptide used in research, purity is not a marketing detail — it is a prerequisite for valid data. A compound that is contaminated, partially degraded, or inaccurately identified will produce noisy or misleading results, and no experimental conclusion drawn from it can be trusted. This is why analytical verification sits at the centre of what distinguishes research-grade material.
High-Performance Liquid Chromatography (HPLC) is the principal technique used to assess peptide purity. HPLC separates the components of a sample and quantifies them, allowing a laboratory to determine what proportion of the material is the intended peptide versus impurities or degradation products. A high HPLC purity figure indicates that the vial contains predominantly the target compound — AOD-9604 — and little else.
Mass spectrometry (MS) frequently accompanies HPLC in peptide characterisation. While HPLC speaks to how pure the sample is, mass spectrometry confirms identity by measuring the molecular weight of the peptide and verifying that it matches the expected value for the hGH 176–191 fragment. Together, the two techniques answer the two questions that matter most: is it the right molecule, and is it clean?
A Certificate of Analysis (COA) is the document that records these results for a specific production batch. A meaningful COA is batch-specific — it reports the actual analytical data for the lot of material being supplied, not a generic specification reused across products. For researchers, the COA is the audit trail that connects the vial on the bench to the verification that was performed on it, and it is a baseline expectation for any reputable source of research peptides.
AOD-9604 is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone (hGH 176–191), with an added N-terminal tyrosine for stability. It is studied in laboratory models for its reported effects on lipid metabolism and is supplied strictly for research use only.
It reproduces only the final 16 amino acids (residues 176–191) of the 191-amino-acid growth hormone molecule. The research interest lies in the hypothesis that this fragment carries growth hormone's fat-metabolism signal while not driving the growth-promoting and IGF-1 actions of the full hormone.
AOD stands for anti-obesity drug, a research designation applied during the early studies that characterised the fragment's metabolic profile in laboratory models. The name reflects the scientific question the compound was developed to investigate, not an approved use.
Research has focused on the fragment's effects on lipolysis (fat breakdown), lipogenesis (fat storage), and fat oxidation in adipocyte cultures and animal models, as well as comparisons with full growth hormone to test whether its metabolic and growth actions can be separated. These findings describe behaviour in experimental systems only.
As a lyophilised powder, it is kept refrigerated for short periods and frozen for longer-term storage, protected from light and moisture. Once reconstituted with a suitable solvent at the bench, the solution is refrigerated, used promptly, and protected from repeated freeze–thaw cycles to preserve peptide integrity.
For research applications, the quality of the material is inseparable from the quality of the data it produces. Alluvia Peptides supplies AOD-9604 5mg manufactured and verified to research-grade standards, including:
Explore the product page for AOD-9604 5mg, or browse the full range of Weight-Loss & Metabolic peptides for related research compounds.
AOD-9604 is intended strictly for laboratory and research use only. It is not for human or animal consumption, and it is not a drug, dietary supplement, or article of food. Nothing in this article constitutes medical, therapeutic, or health advice, and no statement here should be interpreted as a claim that AOD-9604 prevents, treats, cures, or affects any disease or condition in humans, or that it produces weight loss, fat loss, or any other outcome in people. All effects described refer to observations reported in cell-culture and animal-model research and belong to those experimental settings. Any handling of this compound must be carried out by qualified individuals in an appropriate laboratory environment, in accordance with all applicable laws, regulations, and institutional guidelines.